Results of a phase 1 trial for chimeric antigen receptor T cells targeting an orphan receptor in patients with relapsed or refractory multiple myeloma “thrilled” researchers, based on data presented at ASH Annual Meeting and Exhibition.
Recipients of the autologous CAR T cells (BMS-986393, Bristol Myers Squibb), which target GPRC5D, had an 86% overall response rate across all tested doses and a 91% ORR at the phase 2 recommended dose.
“You’re thinking about how this pertains and compares with other things that are already FDA approved,” Susan Bal, MD, malignant
